Sugi Predict

Sugi Predict / Compounds / SCHEMBL1768162

SCHEMBL1768162

SCHEMBL1768162

Cc1ccn2c(C(=O)O)c(C)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ GAA P10253 5/20 0.59
▸ POLB P06746 3/20 0.59
▸ KDM4E B2RXH2 6/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MAPT P10636 2/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ ALDH1A1 P00352 7/20 0.55
▸ HTT P42858 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ CGAS Q8N884 1/20 0.53
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ PKM P14618 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.48
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6112657 0.87 KMT2A (0.64) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL2929154 0.85 GAA (0.58) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL19723534 0.85 GAA (0.58) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL16447604 0.84 SMN1; SMN2 (0.46) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL30770769 0.84 SMN1; SMN2 (0.46) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL20250793 0.83 POLB (0.66) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL17321417 0.83 GAA (0.55) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL12294564 0.81 SMN1; SMN2 (0.50) SMN1; SMN2GAAKDM4EKMT2AMAPT
SCHEMBL21893931 0.81 MAPT (0.45) SMN1; SMN2GAAPOLBKDM4EKMT2A
SCHEMBL6113039 0.81 POLB (0.64) SMN1; SMN2GAAPOLBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209573-A1 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2009-08-20 — — US claimed
EP-1804803-A4 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2008-07-30 — — EP claimed
EP-1804803-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM, LLC (BM) 2007-07-11 — — EP claimed
WO-2006050351-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2006-05-11 — — WO claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 — — CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 — — US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
EP-1804803-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM, LLC (BM) 2007-07-11 — — EP disclosed
WO-2006050351-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2006-05-11 — — WO disclosed
EP-1549650-B1 SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES GRUENENTHAL GMBH (DE) 2006-03-22 — — EP disclosed
US-20050239822-A1 Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines GRUENENTHAL GMBH (DE) 2005-10-27 — — US disclosed
EP-1549650-A1 SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES Grünenthal GmbH (DE) 2005-07-06 — — EP disclosed
WO-2004033453-A1 SUBSTITUTED C-IMIDAZO[1,2-A]PYRIDIN-3-YL-METHYLAMINES Grünenthal GmbH (DE) 2004-04-22 — — WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239822-A1 Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines NOS2, NOS1, NOS3 SMN1; SMN2 1768/4885GAA 1487/4885POLB 2811/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH SMN1; SMN2 3345/4885GAA 290/4885POLB 1982/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885GAA 139/4885POLB 2574/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885GAA 139/4885POLB 2574/4885
US-20090209573-A1 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS GLI1, SHH, SMO SMN1; SMN2 3605/4885GAA 2406/4885POLB 4389/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SMN1; SMN2 3418/4885GAA 94/4885POLB 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.